Vertex Pharmaceuticals Incorporated (VRTX)
VRTX stock forecast: what analysts expect
Wall Street analysts covering Vertex Pharmaceuticals Incorporated currently rate the stock a Buy on average, with a mean 12-month price target of $570.32 — +8.4% versus the last price of $526.19. Targets reflect analyst opinion, not a guarantee.
VRTX historical returns
Based on monthly dividend-adjusted prices. See the full breakdown on what if you had invested in VRTX.
VRTX annual returns by year
Congress trading in VRTX
11 members of Congress have disclosed trading VRTX — 7 purchases and 8 sales worth an estimated $169,000. Most recent disclosure: Aug 26, 2026.
See who in Congress traded VRTX →Insider activity in VRTX
VRTX's own executives and directors have made 0 open-market purchases ($0) and 3 sales ($2.0M) in the last 90 days, per SEC Form 4 filings. Most recent: Jul 2, 2026.
| Jul 2, 2026 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | Sell | $787,485 |
| Jul 2, 2026 | McKechnie Duncan | EVP, Chief Commercial Officer | Sell | $799,779 |
| Jul 1, 2026 | Liu Joy | EVP and Chief Legal Officer | Sell | $416,244 |
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
VRTX Key Statistics
VRTX in plain English
- P/E ratio (30.7) — how many dollars you pay for each $1 of VRTX's yearly profit. That's a fairly normal range.
- ROE (23.54%) — how efficiently the company turns shareholders' money into profit. Above ~20% is considered strong.
- Profit margin (35.00%) — of every $1 in sales, this is what's left as profit after all costs.
- Dividend — VRTX doesn't pay a meaningful dividend; the return here comes from the share price, not cash payouts.
VRTX stock: frequently asked questions
What is Vertex Pharmaceuticals Incorporated's stock price today?
Vertex Pharmaceuticals Incorporated (VRTX) last traded at $526.19 on the NASDAQ. Over the past 52 weeks the stock has traded between $384.39 and $560.25.
Is VRTX stock a buy or a sell?
Wall Street analysts' consensus rating on VRTX is "Buy", with an average 12-month price target of $570.32 — about +8.4% versus the current price of $526.19. Analyst targets are opinions, not guarantees; always do your own research.
How much would $1,000 invested in VRTX 10 years ago be worth today?
A $1,000 investment in Vertex Pharmaceuticals Incorporated made 10 years ago would be worth about $6,034 today (dividends reinvested) — a total return of 503%, or 19.7% per year.
Does VRTX pay a dividend?
No — Vertex Pharmaceuticals Incorporated does not currently pay a meaningful dividend. Returns for shareholders come from changes in the share price.
What is VRTX's P/E ratio?
VRTX trades at a trailing price-to-earnings ratio of 30.7, and 26.2 times expected forward earnings. The P/E ratio tells you how many dollars investors pay for each $1 of the company's annual profit.
Do members of Congress trade VRTX stock?
Yes — 11 members of Congress have disclosed trades in VRTX under the STOCK Act, totaling 7 purchases and 8 sales worth an estimated $169,000.
What is Vertex Pharmaceuticals Incorporated's ticker symbol?
Vertex Pharmaceuticals Incorporated trades under the ticker symbol VRTX on the NASDAQ.
Compare VRTX with peers
Data last refreshed from public sources. Figures may be delayed. Not investment advice.